X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-raises-2024-profit-forecast-strong-cancer-hpv-drugs-sales-2024-04-25/
https://www.globenewswire.com/news-release/2024/04/25/2869506/0/en/HOOKIPA-Pharma-Announces-Pivotal-Phase-2-3-Trial-Design-for-HB-200-in-Combination-with-Pembrolizumab.html
https://www.globenewswire.com/news-release/2024/04/24/2869062/0/en/NextCure-to-Present-Phase-1b-Data-of-NC410-in-Combination-with-Pembrolizumab-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/04/24/2868754/0/en/CG-Oncology-to-Unveil-Encouraging-Results-on-Cretostimogene-in-Combination-with-Pembrolizumab-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/04/24/2868564/0/en/Immutep-Announces-Positive-Preliminary-Topline-Results-from-TACTI-003-Cohort-B.html
https://www.prnewswire.com/news-releases/hanmi-enters-into-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bh3120-in-combination-with-keytruda-pembrolizumab-302125355.html
https://www.globenewswire.com/news-release/2024/04/10/2860723/29489/en/AIM-ImmunoTech-Announces-Positive-Top-Line-Protocol-Planned-Interim-Report-Data-from-the-Study-of-Ampligen-Combined-with-Pembrolizumab-for-the-Treatment-of-Recurrent-Ovarian-Cancer.html
https://www.globenewswire.com/news-release/2024/04/10/2860497/0/en/TILT-Biotherapeutics-Presents-Clinical-Data-on-TILT-123-in-Combination-with-KEYTRUDA-pembrolizumab-for-Ovarian-Cancer-at-AACR-2024.html
https://www.globenewswire.com/news-release/2024/04/05/2858286/0/en/Samsung-Bioepis-Initiates-Phase-3-Clinical-Trial-for-SB27-Proposed-Biosimilar-to-Keytruda-Pembrolizumab.html
https://www.prnewswire.com/news-releases/chinas-national-medical-products-administration-accepts-astellas-and-pfizers-supplemental-biologics-license-application-for-enfortumab-vedotin-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-bladder-cancer-302102654.html
https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-expansion-of-rem-001-clinical-study-to-include-patients-on-pembrolizumab-302100353.html
https://www.globenewswire.com/news-release/2024/03/25/2851479/0/en/BeyondSpring-Announces-First-Patient-Dosed-with-Pembrolizumab-Plinabulin-Plus-Etoposide-Platinum-in-a-Phase-2-Investigator-initiated-Study-of-First-Line-Extensive-Stage-Small-Cell-.html
https://www.globenewswire.com/news-release/2024/03/22/2850878/0/en/HOOKIPA-Pharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html
https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-cervical-cancer-therapy-met-main-goal-late-stage-study-2024-03-15/
https://www.fiercepharma.com/pharma/merck-challenges-johns-hopkins-universitys-keytruda-patents-claims-breach-contract-after
https://www.prnewswire.com/news-releases/ideaya-announces-clinical-collaboration-to-evaluate-ide161-in-combination-with-keytruda-pembrolizumab-in-patients-with-endometrial-cancer-302085972.html
https://www.prnewswire.com/news-releases/padcev-enfortumab-vedotin-genetical-recombination-with-keytruda-pembrolizumab-genetical-recombination-granted-priority-review-by-japans-ministry-of-health-labour-and-welfare-for-first-line-treatment-of-advanced-bladder-302063407.html
https://www.globenewswire.com//news-release/2024/02/13/2828115/0/en/Medicenna-Announces-First-Patient-Dosed-in-ABILITY-1-Study-of-MDNA11-in-Combination-with-KEYTRUDA-pembrolizumab-in-Patients-with-Advanced-Solid-Tumors.html
https://www.globenewswire.com//news-release/2024/02/06/2824137/0/en/BioXcel-Therapeutics-Announces-Completion-of-Patient-Enrollment-in-Safety-Portion-of-Investigator-Sponsored-Phase-2-Relapsed-Pancreatic-Cancer-Trial-of-BXCL701-in-Combination-with-.html
https://www.fiercepharma.com/pharma/whos-no-1-25b-sales-mercks-keytruda-appears-set-be-top-selling-drug-2023
https://endpts.com/merck-highlights-subcutaneous-demand-even-as-keytruda-sales-soar/
https://www.fiercepharma.com/pharma/bristol-myers-unfolds-subcutaneous-opdivo-data-kidney-cancer-i-o-battle-heads-new-front
https://www.prnewswire.com/news-releases/astellas-submits-supplemental-new-drug-application-in-japan-for-padcev-enfortumab-vedotin-genetical-recombination-with-keytruda-pembrolizumab-genetical-recombination-for-first-line-treatment-of-advanced-bladder-cancer-302048608.html
https://endpts.com/merck-details-win-for-keytruda-in-bladder-cancer-after-surgery/
https://www.pfizer.com/news/press-release/press-release-detail/european-medicines-agency-validates-type-ii-variation
https://www.globenewswire.com//news-release/2024/01/16/2810362/0/en/Adagene-Presents-Interim-Results-Reinforcing-Best-in-Class-Profile-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-Metastatic-Microsatellite-s.html
https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-keytruda-combo-gets-fda-nod-expanded-use-cervical-cancer-2024-01-12/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514
https://www.globenewswire.com//news-release/2024/01/09/2806133/0/en/Medicenna-Commences-Enrollment-in-the-ABILITY-1-Study-Combining-MDNA11-with-Pembrolizumab.html
https://www.globenewswire.com//news-release/2024/01/04/2803770/0/en/Adagene-To-Present-Interim-Results-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-MSS-CRC-at-ASCO-GI-Symposium.html
https://www.fiercepharma.com/pharma/merck-astellas-pfizer-bring-down-house-keytruda-padcev-fda-nod-bladder-cancer
https://www.reuters.com/business/healthcare-pharmaceuticals/benefits-moderna-merck-melanoma-vaccine-plus-keytruda-extend-three-years-2023-12-14/
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-eisais-cancer-therapy-combo-fails-late-stage-study-2023-12-08/
https://www.businesswire.com/news/home/20231207532705/en/Merck-Announces-KEYLYNK-008-Trial-Evaluating-KEYTRUDA%C2%AE-pembrolizumab-Plus-LYNPARZA%C2%AE-olaparib-for-Patients-With-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer-to-Stop-for-Futility
https://www.prnewswire.com/news-releases/curis-enters-into-agreement-for-emavusertib--pembrolizumab-combination-study-in-melanoma-302005577.html
https://www.merck.com/news/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of-patients-with-locally-advanced/
https://www.fiercepharma.com/marketing/coherus-prices-china-made-pd-1-drug-loqtorzi-20-discount-mercks-keytruda
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction
Market Place
Share 
